Search results for "Metformin"

showing 10 items of 126 documents

Influence of metformin on GLUT1 gene and protein expression in rat streptozotocindiabetes mellitusmodel

2010

Metformin improves hyperglycaemia via mechanisms which include activation of AMP-activated protein kinase (AMPK). Recent findings indicate that some metabolic actions of metformin occur also by AMPK-independent mechanisms.To study the action of metformin on expression of GLUT1 glucose transporter in rat streptozotocin model of diabetes mellitus.Streptozotocin-induced rats were treated with metformin while monitoring parameters of carbohydrate and lipid metabolism. GLUT1 mRNA and protein expression in kidneys, heart, liver and muscles were studied by means of real time quantitative RT-PCR and immunohistochemistry correspondingly.Metformin treatment decreased glucose concentration, glycated h…

Maleendocrine systemmedicine.medical_specialtyendocrine system diseasesPhysiologyCarbohydrate metabolismDiabetes Mellitus ExperimentalPhysiology (medical)Internal medicineDiabetes mellitusmedicineAnimalsHypoglycemic AgentsRats WistarGlycated HemoglobinGlucose Transporter Type 1Glucose tolerance testmedicine.diagnostic_testbiologybusiness.industrydigestive oral and skin physiologyGlucose transporternutritional and metabolic diseasesAMPKGeneral MedicineGlucose Tolerance TestStreptozotocinmedicine.diseaseMetforminRatsMetforminDisease Models AnimalGlucoseEndocrinologyGene Expression Regulationbiology.proteinGLUT1businessmedicine.drugArchives of Physiology and Biochemistry
researchProduct

Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An …

2019

AIM: To evaluate the effect of exenatide long acting release (LAR) on carotid intima-media thickness (IMT) and endothelial function in patients with type 2 diabetes mellitus. METHODS: Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study. Anthropometric variables, lipid profile and glycemic parameters were assessed by routine analysis. Carotid IMT by Doppler ultrasound and endothelial function by flow-mediated dilation of the brachial artery were also assessed. RESULTS: Exenatide significantly improved fasting glycaemia (from 8.8 ± 2.8 to 7.3 ± 2.2 mmol/L, p < 0.0001), HbA1c (from 8.0 ± 0.4 …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetesCarotid Intima-Media ThicknessCarotid intima-media thickne03 medical and health sciences0302 clinical medicineEndocrinologyRisk FactorsInternal medicineDiabetes mellitusInternal MedicineMedicineHumansHypoglycemic Agentscardiovascular diseases030212 general & internal medicineProspective StudiesEndothelial dysfunctionmedicine.diagnostic_testbusiness.industryType 2 Diabetes MellitusGeneral MedicineMiddle Agedmedicine.diseaseCardiovascular diseaseAtherosclerosisMetforminIntima-media thicknessDiabetes Mellitus Type 2Atherosclerosicardiovascular systemCardiologyExenatideFemalebusinessLipid profileExenatidemedicine.drugDiabetes research and clinical practice
researchProduct

Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.

2014

Background Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown. Methods A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound. Results After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholester…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismPilot ProjectsType2 diabetesType 2 diabetesCarotid Intima-Media ThicknessCoronary artery diseaseGlucagon-Like Peptide 1Internal medicineDiabetes mellitusLiraglutide Carotid intima-media thickness Cardiovascular risk Type2 diabetesmedicineHumansHypoglycemic AgentsProspective Studiescardiovascular diseasesProspective cohort studyGlycemicAgedOriginal Investigationbusiness.industryLiraglutideLiraglutideMiddle Agedmedicine.diseaseCardiovascular risk3. Good healthMetforminEndocrinologyIntima-media thicknessDiabetes Mellitus Type 2Cardiologycardiovascular systemFemalebusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Trea…

2018

AbstractWe investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function in patients with T2DM insufficiently controlled on metformin monotherapy during a hyperglycaemic clamp investigation. Twenty-six patients (19 males, age 63.5±7.0 years; duration of diabetes 8.8±4.7 years; HbA1c 63.9±15.8 mmol/mol; mean±SD) were enrolled in the study. During a first treatment period (TP1) all patients received 10 mg dapagliflozin for one month, followed by the addition of 5 mg saxagliptin or placebo for another month (TP2). At baseline and at the end of each treatment period, fasting glucose and insulin levels were analysed, and a hyperglycaemic clam…

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryAdamantane030209 endocrinology & metabolism030204 cardiovascular system & hematologySaxagliptinBiochemistryGlucagon03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceDouble-Blind MethodGlucosidesInsulin-Secreting CellsInternal medicineDiabetes mellitusmedicineHumansBenzhydryl CompoundsDapagliflozinAgedProinsulinbusiness.industryInsulinBiochemistry (medical)DipeptidesGeneral MedicineMiddle Agedmedicine.diseaseMetforminEndocrinologyDiabetes Mellitus Type 2chemistryFemalebusinessmedicine.drugHormone and Metabolic Research
researchProduct

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

2010

AIM Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin. MATERIAL AND METHODS Overall, 28 insulin-naive type 2 diabetes subjects (mean +/- SD age, 61.5 +/- 6.7 years; diabetes duration, 9.8 +/- 6.5 years; HbA1c, 7.1 +/- 0.5%; BMI, 30.7 +/- 4.3 kg/m(2)) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentInsulin IsophaneInsulin GlarginePilot ProjectsNPH insulinType 2 diabetesNPH insulinDrug Administration ScheduleEndocrinologyInsulin-Secreting CellsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinintact proinsulinGlycated Hemoglobinbusiness.industryInsulin glargineInsulindigestive oral and skin physiologynutritional and metabolic diseasesFastingOriginal ArticlesMiddle AgedPostprandial Periodmedicine.diseaseMetforminMetforminInsulin Long-ActingEndocrinologyPostprandialDiabetes Mellitus Type 2beta cell stressDrug Therapy CombinationFemalebusinessmedicine.drugBlood samplingDiabetes, Obesity and Metabolism
researchProduct

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006

BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary…

Malemedicine.medical_specialtyUrologyKaplan-Meier EstimateType 2 diabetesPharmacologyWeight GainRosiglitazoneGlibenclamidechemistry.chemical_compoundDouble-Blind MethodDiabetes mellitusGlyburidemedicineHumansHypoglycemic AgentsProportional Hazards ModelsGlycemicGlycated HemoglobinGlycemic efficacyWaist-Hip Ratiobusiness.industryCholesterol LDLGeneral MedicineMiddle Agedmedicine.diseaseMetforminMetforminTreatment OutcomeDiabetes Mellitus Type 2chemistryCardiovascular DiseasesFemaleThiazolidinedionesGlycated hemoglobinbusinessRosiglitazonemedicine.drugNew England Journal of Medicine
researchProduct

Metformin and contrast-induced acte kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevati…

2016

IF 4.638; International audience; AIM : To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI).METHODS: Patients with type 2 diabetes mellitus (T2DM) treated with PCI 27μmol/l (0.3mg/dl) or >50% over baseline after PCI. Since PCI was urgent, metformin could not be withheld prior to PCI but was usually stopped after PCI.RESULTS:Among the 372 patients included, 147 (40%) were using metformin, which had older diabetes, but had risk factors similar to patients without metformin. Baseline eGFR was better in pati…

Malemedicine.medical_specialtyendocrine system diseasesMedication Therapy Managementmedicine.medical_treatmentStatistics as TopicContrast Media030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessment03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedbusiness.industryPrimary percutaneous coronary interventionAcute kidney injuryPercutaneous coronary interventionnutritional and metabolic diseasesMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseST segment elevation segment myocardial infarctionMetformin3. Good healthMetforminAcute kidney injuryDiabetes Mellitus Type 2CreatinineConventional PCICardiologyST Elevation Myocardial InfarctionFemaleFranceCardiology and Cardiovascular MedicinebusinessKidney diseasemedicine.drug
researchProduct

Association of prestroke metformin use, stroke severity, and thrombolysis outcome

2020

ObjectiveTo evaluate whether pretreatment with metformin (MET) is associated with less stroke severity and better outcome after IV thrombolysis (IVT), we analyzed a cohort of 1,919 patients with stroke with type 2 diabetes mellitus in a multicenter exploratory analysis.MethodsData from patients with diabetes and ischemic stroke treated with IVT were collected within the European Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration. We applied propensity score matching (PSM) to obtain balanced baseline characteristics of patients treated with and without MET.ResultsOf 1,919 patients with stroke with type 2 diabetes who underwent IVT, 757 (39%) had received MET before stroke (MET+),…

Malemedicine.medical_specialtymedicine.medical_treatment610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsModified Rankin ScaleInternal medicineDiabetes mellitusEpidemiologymedicineHumansHypoglycemic AgentsThrombolytic Therapycardiovascular diseases10064 Neuroscience Center ZurichStrokeAgedRetrospective Studiesbusiness.industryRecovery of Function10060 Epidemiology Biostatistics and Prevention Institute (EBPI)ThrombolysisMiddle Agedmedicine.diseaseMetformin10040 Clinic for Neurology3. Good healthMetforminStroke2728 Neurology (clinical)Diabetes Mellitus Type 2Propensity score matchingCohortFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugNeurology
researchProduct

Pharmacologic therapies in endometriosis: a systematic review

2012

To assess the literature on preclinical and clinical efficacy and safety data of pharmacologic groups proposed in the treatment of endometriosis, we performed a systematic review of publications from March 2002 to January 2012 via PubMed search. Additional relevant articles were identified from citations within these publications. A high number of medications were tested in preclinical models of endometriosis due to their theoretic capacity of disrupting important pathophysiologic pathways of the disease, such as inflammatory response, angiogenesis and cell survival, proliferation, migration, adhesion, and invasion. Tumor necrosis factor α-blockers, nuclear factor κB inhibitors, antiangioge…

Matrix metalloproteinase inhibitorAngiogenesisAnti-Inflammatory AgentsEndometriosisEndometriosisAngiogenesis InhibitorsPharmacologyp38 Mitogen-Activated Protein KinasesAntioxidantsEtanerceptmedicineAnimalsHumansHyaluronic AcidAdverse effectMelatoninTumor Necrosis Factor-alphabusiness.industryNF-kappa BObstetrics and Gynecologymedicine.diseaseMetforminReproductive MedicineEstrogen inhibitorFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsEndostatinbusinessmedicine.drugFertility and Sterility
researchProduct

Controlled Release of Metformin Hydrochloride from Core-Shell Nanofibers with Fish Sarcoplasmic Protein

2019

Ficai, Anton/0000-0002-1777-0525; Karademir, Betul/0000-0003-1762-0284 WOS:000503463400074 PubMed ID: 31658758 Background and Objectives: A coaxial electrospinning technique was used to produce core/shell nanofibers of a polylactic acid (PLA) as a shell and a polyvinyl alcohol (PVA) containing metformin hydrochloride (MH) as a core. Materials and Methods: Fish sarcoplasmic protein (FSP) was extracted from fresh bonito and incorporated into nanofiber at various concentrations to investigate the influence on properties of the coaxial nanofibers. The morphology, chemical structure and thermal properties of the nanofibers were studied. Results: The results show that uniform and bead-free struct…

Medicine (General)POLYMERIC NANOFIBERSChemical structurewound healingIn Vitro Techniquescoaxial electrospinningPolyvinyl alcoholArticleDELIVERYCrystallinitychemistry.chemical_compoundcoaxial electrospinning; fish sarcoplasmic protein; nanofibers; wound healingR5-920Differential scanning calorimetryPolylactic acidnanofibersSpectroscopy Fourier Transform InfraredMedicineAnimalsbusiness.industryTunaGeneral MedicineControlled releaseMetforminfish sarcoplasmic proteinDrug LiberationSarcoplasmic ReticulumchemistryChemical engineeringNanofiberDelayed-Action PreparationsPolyvinyl AlcoholELECTROSPUN NANOFIBERSCoaxialbusinessFIBERSMATRICES
researchProduct